DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow turns negative
Q1 FY2026 investing cash flow was -$2.11M, compared with $6.62M a year earlier. Trailing-twelve-month investing cash flow was -$11.37M.
Context
- Investing cash flow increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly investing cash flow holds near -$2.11M or moves back toward the trailing-twelve-month quarterly average of -$2.84M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (2.19M) USD
- Year-over-year change
- -125.6%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.19M) | -125.6% |
| FY2024 | 2024-12-31 | 8.56M | +146.8% |
| FY2023 | 2023-12-31 | (18.3M) | -258.6% |
| FY2022 | 2022-12-31 | 11.54M | +156.2% |
| FY2021 | 2021-12-31 | (20.54M) | — |
Investing Cash Flow vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 investing cash flow of $11.37M is the 6th largest of the 7 companies compared; the peer median is $12.69M.
- Its year-over-year change of -203.5% is the 6th highest of 7, against a peer median of +610.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $164.39M | +13986.4% | +277.8% | 821.9% | |
| LTM Mar 2026 | $110.5M | +1239.7% | — | 12430.0% | |
| LTM Jun 2026 | $68.98M | -84.4% | — | 1914.0% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $63.98M | -18.3% | +874.1% | 620.2% |
| LTM Mar 2026 | $17.23M | +20917.1% | +1721.9% | — | |
| LTM Mar 2026 | $11.37M | -203.5% | — | — | |
| LTM Mar 2026 | $8.14M | -6828.9% | +311.2% | 3.5% | |
| Peer median (excluding DMAC) | $12.69M | +610.7% | +592.7% | 821.9% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | (899K) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.56M | 1.5M | 1.68M | 2.09M | 3.85M |
| Change in Working Capital | (461K) | 585K | 93K | 1.51M | 675K |
| Accounts Receivables | 210K | 48K | (287K) | 133K | (22K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (590K) | 225K | 192K | 14K | 535K |
| Other Working Capital | (81K) | 312K | 188K | 1.37M | 162K |
| Other Non-Cash Items | 219K | 53K | (1.15M) | (1.27M) | 82K |
| Operating Cash Flow | (12.25M) | (11.51M) | (18.73M) | (22.08M) | (29.06M) |
| Capital Expenditures | (22K) | (81K) | (24K) | (25K) | (40K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (69.81M) | (45.68M) | (69.41M) | (50.41M) | (59.28M) |
| Sales of Investments | 49.3M | 57.3M | 51.14M | 59M | 57.13M |
| Other Investing Activities | 2K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (20.54M) | 11.54M | (18.3M) | 8.56M | (2.19M) |
| Debt Repayment | (6K) | (6K) | (6K) | (9K) | (10K) |
| Common Stock Issued | 29.85M | 0 | 36.85M | 11.75M | 44.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 244K | 0 | 0 | 256K | (400K) |
| Financing Cash Flow | 30.09M | (6K) | 36.84M | 11.99M | 43.88M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (2.7M) | 21K | (185K) | (1.52M) | 12.62M |
| Free Cash Flow | (12.27M) | (11.59M) | (18.75M) | (22.1M) | (29.1M) |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.